期刊
IMMUNOLOGICAL INVESTIGATIONS
卷 50, 期 5, 页码 562-579出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/08820139.2020.1778721
关键词
Neoantigen; intra-nodal administration; dendritic cell vaccine; epitope-specific T cell; malignant ascites
类别
The study demonstrates the clinical and immunological effects of neoantigen peptide-loaded DC-based immunotherapy in a patient with chemorefractory ovarian cancer. The treatment led to a significant decrease in CA-125 levels and improvements in tumor-related symptoms.
Chemorefractory ovarian cancer has limited therapeutic options. Hence, new types of treatment including neoantigen-specific immunotherapy need to be investigated. Neoantigens represent promising targets for personalized cancer immunotherapy. We here describe the clinical and immunological effects of a neoantigen peptide-loaded DC-based immunotherapy in a patient with recurrent and chemoresistant ovarian cancer. A 71-year-old female patient with chemorefractory ovarian cancer and malignant ascites received intranodal vaccination of DCs loaded with four neoantigen peptides that were predicted by our immunogenomic pipeline. Following four rounds of vaccinations with this therapy, CA-125 levels were remarkably declined and tumor cells in the ascites were also decreased. Concordantly, the tumor-related symptoms such as respiratory discomfort improved without any adverse reactions. The reactivity against one HLA-A2402-restricted neoantigen peptide derived from a mutated PPM1 F protein was detected in lymphocytes from peripheral blood by IFN-gamma ELISPOT assay. Furthermore, the neoantigen (PPM1 F mutant)-specific TCRs were detected in the tumor-infiltrating T lymphocytes post-vaccination. Our results showed that vaccination with intranodal injection of neoantigen peptide-loaded DCs may have clinical and immunological impacts on cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据